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Objective: To assess the impact of reference pricing and extension of generic substitution on the daily cost of
antipsychotic drugs in Finland during the first year after its launch. Furthermore, the additional impact of reference
pricing on prior implemented generic substitution is assessed.
Methods: A retrospective analysis was performed between 2006 and 2010. A segmented linear regression analysis
of interrupted time series was used to estimate changes in the levels and trends in the cost of one day of treatment. Of
the study drugs, clozapine belonged to generic substitution already at the start of the study period while olanzapine
and quetiapine were included in generic substitution alongside with reference pricing in 2009. Risperidone was included
in generic substitution in 2008, before reference pricing.
Results: A substantial decrease in the daily cost of all four antipsychotic substances was seen after one year of the
implementation of reference pricing and the extension of generic substitution. The impact ranged from -29.9% to
-66.3%, and it was most substantial on the daily cost of olanzapine. Also in the daily cost of risperidone a substantial
decrease of -43.3% was observed. However, most of these savings, -32.6%, were generated by generic substitution which
had been adopted prior.
Conclusions: Reference pricing and the extension of generic substitution produced substantial savings on antipsychotic
medication costs during the first year after its launch, but the intensity of the impact differed between active substances.
Furthermore, our results suggest that the additional cost savings from reference pricing after prior implemented generic
substitution, are comparatively low.
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Pharmaceutical expenditures have been growing rapidly
in most European countries exceeding the growth in
overall health spending [1]. This is a source of concern
to governments and several strategies for reducing or
slowing down public expenditure on pharmaceutical
products have been discussed and implemented. Essen-
tially, cost containment measures for pharmaceuticals
aim to control prices of medicines, or influence de-
mand by implementing financial or professional mea-
sures [2,3].* Correspondence: hanna.koskinen@kela.fi
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in any medium, provided the original work is pReference pricing in drug reimbursement is a widely
used cost containment method. It was first formally
adopted in Germany in 1989 followed by many of the
European Union countries, as well as New Zealand,
Australia and Canada among others [4,5]. In reference-
based pricing, pharmaceuticals are classified into clusters
based on generic groups, related drug groups or groups
according to similar therapeutic effects. The payer then
sets a reference price for each cluster based on e.g. either
the lowest or the average price of drugs in that group. The
reference price defines the maximum reimbursement
for all products in the group. Drugs priced at or below
the reference price are subsidized while drugs above the
reference price require the patient to pay the excess in
part or in total. Rather than to constrain the overalls an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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is to control the third-party expenditure on prescription
drugs [5,6].The reasoning behind reference pricing is to
stimulate competition and rational decision-making by
physicians and consumers [4]. It is not a direct price
control, as manufacturers are free to set a price higher
than the reference price.
Studies have shown that the introduction of reference
price system generates significant savings during the first
years of application. Furthermore, reference price sys-
tems have generally been associated with a decrease in
the prices of the drugs subject to the policy, and more
significant price decreases have been observed in the
sub-markets where the drugs were already facing generic
competition prior to reference pricing [7]. A German
study found that the introduction of reference price
system reduces prices of the affected products by ap-
proximately 7% [8]. In Sweden, drugs covered by the
reference price system faced an average price decrease of
19% in the first year after the introduction of the system
[9]. Similar results, an estimated price decrease of 18%,
were seen in Norway for brand name products while the
price reduction for generics was estimated to be about
8%. [10] On the other hand, though the initial average
price reduction after the introduction of reference price
system in The Netherlands was about 5%, the system
also had some negative implications as the prices of
several generic drugs were raised towards the maximum
reimbursement level [11].
In Finland, generic substitution was introduced in
April 2003 and reference pricing in April 2009. Generic
substitution systems can vary between countries but ba-
sically in generic substitution pharmacies have the right
or obligation to substitute the cheapest or close to the
cheapest equivalent medicine for a prescribed medicine
[12]. As reference pricing and generic substitution were
implemented at different times in Finland, we are able to
study the additional impact of reference pricing to a mar-
ket already faced with generic competition. So far, to
our knowledge, there have been no studies examining the
additional impact of reference pricing to prior imple-
mented generic substitution.
Our specific interest is to study the impact of reference
pricing to the daily cost of antipsychotic drugs. Antipsy-
chotics, which are primarily indicated for the treatment of
psychotic disorders such as schizophrenia and schizoaffec-
tive disorder [13], have in terms of costs been among the
fastest-growing therapeutic classes in Finland in the past
decades, and the growth was mostly explained by the
average cost per one day of treatment [14]. Antipsychotics
were not originally included in generic substitution
in Finland because of concerns with adherence [15]. How-
ever, this decision was later changed and from 2006 on-
wards antipsychotics were considered to be substitutable,provided they otherwise meet the criteria for substitut-
ability. Clozapine, olanzapine, quetiapine and risperi-
done are among the most used atypical antipsychotics
in Finland [16], and were therefore selected for this
study. The selected study drugs were included in generic
substitution and reference pricing at different times
during the study period. The aim of this study is to as-
sess the impact of reference pricing on the daily cost of
antipsychotic drugs in Finland during the first year after
its implementation. Furthermore, the additional impact of




All permanent residents in Finland are covered by the
National Health Insurance scheme, which among other
things provides reimbursements for the cost of prescription
drugs used in ambulatory care. The rate of the reimburse-
ment varies between drug groups and diagnoses, and
during the study years it was either 42% (basic refund
category) or 100% plus a fixed co-payment of €3.00 per
purchase (higher special refund category) for all of the
studied antipsychotics. The higher special reimbursement
is available for antipsychotics when used in the treatment
of severe psychotic and other severe mental disorders. Re-
gardless of the refund category, the patient’s annual share
of the costs cannot exceed a set limit, which was €672.70
in 2010 [17].
Reference pricing was adopted in Finland in April 2009
in tandem with extending the range of medicinal products
available for generic substitution. The extension to generic
substitution was done by including medicinal products
protected by analogy process patent to the scope of substi-
tutable products. The aim of reference pricing was to fur-
ther enhance the savings generated by generic substitution,
which had been adopted in April 2003.
In Finland, it was not possible to grant product patents
for medicinal substances prior to 1995, only so called
analogy process patents were possible. In order to pro-
tect the intellectual property of process patent holders in
Finland, the Finnish Medicines Act was amended in 2006
so that pharmaceuticals were excluded from the generic
substitution system if they were protected by analogous
process patent in Finland and they enjoyed product patent
protection in at least five other European Economic
Area countries. However, when a generic reference price
system was approved by the Finnish government, it was
also decided that pharmaceuticals protected by analo-
gous process patent would be included in the sphere
of generic substitution (Amendment 803/2008 on
Medicines Act [395/1987]). Clozapine was included in
generic substitution in January 2006 and risperidone
in January 2008. Olanzapine and quetiapine, both
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generic substitution alongside with reference pricing in
April 2009 (Table 1).
In generic substitution system in Finland, the dispens-
ing pharmacy is obligated to substitute the prescribed
medicine to the cheapest, or close to cheapest, product
containing the same active substance. Mutually substi-
tutable medicinal products are grouped according to the
following criteria: they must have the same active ingre-
dient, the same strength and same pharmaceutical form,
and they must be sold in comparable package sizes. The
reference price groups are based on the list for substitutable
medicinal products compiled by the Finnish Medicines
Agency Fimea. A reference price for a group is then set at
€1.50 higher than the price of the cheapest product in the
group if the cheapest product is priced below €40.00. If the
cheapest product is priced at €40.00 or more, the reference
price is set €2.00 higher than the cheapest one. Reference
prices are subject to changes on a quarterly basis. Patients
who wish not to switch to a cheaper medicine are reim-
bursed according to the reference price, and they must
pay the excess themselves. The excess does not count
towards the annual limit of out-of-pocket medicine ex-
penses. However, the prescribing doctor may prohibit
substitution on medical or therapeutic grounds, in
which case the reimbursement is calculated according
to the purchase price [17]. Before the reference price
system was introduced, both the prescribing physician
and the purchasing individual could reject the substi-
tution without affecting the reimbursement rate of the
product [18]. Besides the implementations of generic
substitution and reference pricing, the reimbursement
system in Finland remained substantially unchanged
through the study period.
Data collection
The Social Insurance Institution of Finland maintains a
national register, which contains information on reim-
bursed purchases of medicines. Between 2006 and 2010,
the register covered 94-99% of the ambulatory consump-
tion of antipsychotics measured as Defined Daily Doses
(DDDs). The data extracted for this study includes
information on the patient identity number, the date of
dispensing, the total cost of the purchase, AnatomicalTable 1 Information about the active substances included in
Active ingredient Marketing authorization Generic substitution Re
Clozapine 1990 1st Jan 2006 1st
Olanzapine 1996 1st Apr 2009 1st
Quetiapine 2001 1st Apr 2009 1st
Risperidone 1994 1st Jan 2008 1stTherapeutic Chemical (ATC) classification code [19] of
the product, and the number of DDDs purchased. The
concept of DDD was developed for drug consumption
statistics, and it represents the typical daily dose for a
drug when it is used for its main indication in adults
[19]. The Social Insurance Institution’s register does not
include information on the actual prescribed dosage of the
drug. Therefore, DDD was used as a proxy for a daily dos-
age. The DDDs used in this analysis are for the year 2010.
The costs used are retail prices inclusive of value-added
tax, and they include both the National Health Insurance
scheme’s reimbursement part of the price and the patient’s
own contributions.
The study data consisted of reimbursed purchases of
clozapine (ATC classification code N05AH02), olanza-
pine (N05AH03), quetiapine (N05AH04) and risperidone
(N05AX08) from January 1, 2006 to March 31, 2010.
Statistical analysis
An interrupted time series design and segmented linear
regression analysis were used to estimate changes in the
levels and trends in the cost of one day of treatment
(daily cost) measured as the cost per DDDs after the
introduction of generic substitution and reference pri-
cing. Segmented linear regression analysis of interrupted
time series allows us to evaluate longitudinal effects of
interventions. It takes account of the pre-intervention
level and trend of the daily cost and assesses how much
the intervention changes the cost immediately and over
time in absolute and relative terms.
Our study material allowed the analysis of the daily
cost of clozapine, olanzapine and quetiapine products
39 months before and 12 months after the introduction
of reference pricing. Clozapine belonged to generic
substitution already at the start of the study period
while olanzapine and quetiapine were included in generic
substitution at the start of reference pricing. Risperidone
was included in generic substitution before reference
pricing, and the study material covered 24 months before
generic substitution, 15 months after generic substitution
but before reference pricing, and 12 months after refer-
ence pricing. A mean monthly daily cost was calculated
for each of the antipsychotics. Altogether, each dataset
had 51 monthly values of the mean daily cost.the study
ference pricing Total costs (EUR) Purchasing individuals (n)
2006 2010 2006 2010
Apr 2009 4,457,941 5,356,410 7,773 9,227
Apr 2009 37,287,194 21,819,898 20,151 22,857
Apr 2009 23,076,154 20,235,274 29,793 65,351
Apr 2009 21,411,458 16,780,347 28,997 37,220
Koskinen et al. Health Economics Review 2014, 4:9 Page 4 of 10
http://www.healtheconomicsreview.com/content/4/1/9The following segmented linear regression model with
autoregressive errors was used for clozapine, olanzapine
and quetiapine [20,21]:
Yt ¼ β0 þ β1  timet þ β2  interventiont þ β3
 time after interventiont þ νt
νt ¼ –φ1νt‐1–…:–φnνt‐n þ εt εt e IN 0; σ2ð Þ
In this model Yt is the mean daily cost of the study
medication in month t; time is a continuous variable in-
dicating time in month at time t from the start of the
observation period; intervention is an indicator for time
t, coded 0 before reference pricing and 1 after it; time
after intervention received a value of 0 before reference
pricing and was a continuous variable indicating time in
months after the change; β0 estimates the baseline level
of daily cost per month; β1 estimates the monthly
change in daily cost before reference pricing; β2 esti-
mates the level of change in daily cost immediately after
the introduction of reference pricing; β3 estimates the
change in the trend of daily cost after reference pricing,
compared with the monthly trend before reference pri-
cing; and νt is an error term consisting of an autoregres-
sive error part – φ1νt-1 – …. – φnνt-n and a random error
part εt. All parameters β0, β1, β2 and β3 that were signifi-
cant at significance level 0.10 were included in the final
models.
As error terms may be correlated in time-series data,
the Durbin-Watson test was applied. Autocorrelation
was detected in all of the datasets, and thus autoregressive
error models were used to estimate the regression param-
eters with control of autocorrelation. The estimations
were done using maximum likelihood methods, which is
considered one of the most appropriate approaches for
small samples with autocorrelated errors [21,22]. All
significant autoregressive parameters up to 12 months
were included in the models, and stepwise elimination
with significance level 0.10 was used. In the results sec-
tion, the autoregressive parameters are assumed fixed, and
they are valued according to their estimated values.
The normality and homoscedasticity of the residuals
were checked by statistical tests, and graphic analysis of
residuals was done to provide information about the
consistency. Although statistical tests supported the
assumption of homoscedasticity in the olanzapine data,
graphical examinations indicated the possibility of the
presence of heteroscedasticity: the scatter plot of times
and residuals suggested that the variable time might be
the source of heteroscedasticity. Therefore, a model with-
out a time variable was also fitted in the olanzapine data.
The following segmented linear regression model with
autoregressive errors with two change points was used
for risperidone [20,21]:Yt ¼ β0 þ β1  timet þ β2  pret þ β3  intervention1t
þβ4  time after intervention1t þ β5  intervention2t
þβ6  time after intervention2t þ νt
νt ¼ –φ1νt‐1–…:–φnνt‐n þ εt εt e IN 0; σ2ð Þ
In this model, β2 estimates the pre-effect to generic
substitution; pret is a dummy variable receiving a value
of 1 one month before generic substitution was imple-
mented and a value of 0 at all other time points; interven-
tion1 refers to generic substitution; and intervention2 refers
to reference pricing.
The estimations, as well as the checking of normality
and homoscedasticity of residuals, were done according to
the methods described in the case of clozapine, olanzapine
and quetiapine.
First, a model without the pre-effect to generic substitu-
tion was tried. In that case, a departure from the assump-
tion of homoscedasticity of the residuals was detected.
Further investigation identified an outlier as the source
of the heteroscedasticity. The outlier was identified as
December 2007, indicating that the manufacturers were
anticipating the forthcoming generic substitution. There-
fore, a dummy variable estimating the pre-effect to generic
substitution was constructed for the risperidone model.
The confidence intervals for absolute and relative
changes in the daily cost were calculated using bootstrap
methods. A bootstrap algorithm based on the theoretical
framework of Zhang et al. was constructed [21]. The
algorithm consists of five phases. The estimated values
of the parameters used below were received from the
model fitted to the original data.
1. Fitted values Ybt were computed for all t = 1,…, 51:
Ybt ¼ βb0 þ βb1  timet þ βb2  interventiont þ βb3
 time after interventiont; for clozapine; olanzapine
and quetiapine andquetiapine and
Ybt ¼ βb0 þ βb1  timet þ βb2  pret þ βb3  intervention1t
þβb4  time after intervention1t þ βb5  intervention2t




6 of the parameters
β0, β1,…,β6 were used and only the significant
parameters were involved.
2. Next three phases were repeated 10 000 times.
a. Simulated values ν̃t ; t = 1, …, 51 were drawn from
the model
νt ¼ ‐φ^1νt‐1‐…‐φ^nνt‐n þ εt
εt
e
IN 0; σ^2ð Þ
The estimated values φ^ ;…; φ^ of the parameters1 n
φ1,…, φn were used and only the significant
Koskinen et al. Health Economics Review 2014, 4:9 Page 5 of 10
http://www.healtheconomicsreview.com/content/4/1/9parameters were involved. The root mean square
error (RMSE) was used as the estimated value σ^
of the parameter σ. An exact simulation
algorithm as described in Woodfield [23] was
used (SAS/IML function ARMASIM).
b. New simulated data ~Yt ¼ Y^t þ ~νt , t = 1, …, 51,
was created.
c. The model with the same structure as in the
model fitted to the original data was fitted to the
new simulated data and the new estimated values
of the parameters received were stored.
3. The stored collection of the new estimated values is
the empirical distribution of the estimated values
and was used when confidence intervals were
calculated.
All analyses were conducted using SAS 9.2 [24].
Results
Between January 1, 2006 and March 31, 2010, there were
402,869 purchases of clozapine, 380,680 purchases of
olanzapine, 697,026 purchases of quetiapine, and 498,339
purchases of risperidone.
The results of the regression model for clozapine
are presented in Table 2. Though the 95 percent
confidence intervals include zero, during the gene-
ric substitution period the daily cost of clozapine had
a downward month-to-month trend and this trend
accelerated after reference pricing when significance
level 0.10 is used. Immediately after reference pricing
was implemented, the level of the daily cost dropped
substantially (Figure 1a).
For olanzapine, a downward month-to-month trend
was observed already before generic substitution and
reference pricing were introduced. Immediately after the
implementation, the level of the daily cost dropped by
€1.58, and the downward month-to-month trend accel-
erated (Table 3, Figure 1b). As the scatter plot of times
and residuals suggested the possibility of heteroscedasti-
city, the consistency of the estimates was checked by
omitting time variable from the model. The results proved
to be robust.
The results from the regression model for quetiapine
are presented in Table 4. The regression curve (Figure 1c)
has the same shape as in the case of olanzapine: a down-
ward month-to-month trend before generic substitutionTable 2 Impact of reference pricing on the daily cost of cloza
Estimate
Level before reference pricing (β0) 2.3008
Trend before reference pricing (β1) −0.0031
Level change after reference pricing (β2) −0.4676
Trend change after reference pricing (β3) −0.0145and reference pricing were introduced, a substantial
drop in the level of the daily cost immediately upon
implementation, and an acceleration in the trend after
the implementation.
The daily cost of risperidone had a slight but statisti-
cally significant upward trend before generic substitution
was implemented, but this trend turned downward after
generic substitution. Immediately after also reference
pricing was implemented, the level of the daily cost of
risperidone dropped substantially (Table 5, Figure 2).
There was no statistically significant (P = 0.1426) change
in the month-to-month trend after reference pricing was
implemented, and therefore this factor was eliminated
from the model.
The absolute and relative effects of reference pricing
to the average daily cost of the study drugs after one
year of application are presented in Table 6. For cloza-
pine, without the implementation of reference pricing
the estimated daily cost would have been €2.14. With
reference pricing, the estimated daily cost was €1.50,
representing an absolute reduction of €0.64 and a rela-
tive reduction of 29.9%. For olanzapine, the absolute and
relative reductions were even more substantial, €3.05
and 66.3%, respectively. The corresponding numbers for
quetiapine were €1.66 and 34.9%. In the case of risperidone,
the relative reduction the daily cost after one year of the
implementation of reference pricing was 43.3%. How-
ever, a substantial part of the savings was generated by
generic substitution, and the estimated daily cost of
risperidone at the end of the study period would have
been €4.99 if reference pricing had not been imple-
mented. That corresponds to a relative change of
−32.6% (95% CI −35.2%, −30.0%).
Discussion
In our study, a substantial decrease in the daily cost of
all four antipsychotics was seen after one year of the im-
plementation of reference pricing. The intensity of the
impact, however, differed between different active sub-
stances. Furthermore, as generic substitution and refer-
ence pricing were implemented at different times in
Finland, we were able to study the additional impact of
reference pricing on prior implemented generic substitu-
tion and our results suggest that the additional impact of
reference pricing remains comparably small. The result
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Figure 1 Daily cost trends of clozapine, olanzapine and quetiapine. a Observed and predicted daily cost of clozapine and the forecast cost
had reference pricing not been implemented (EUR). b Observed and predicted daily cost of olanzapine and the forecast cost had generic substitution
and reference pricing not been implemented (EUR). c Observed and predicted daily cost of quetiapine and the forecast cost had generic substitution
and reference pricing not been implemented (EUR).
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can partly be explained by different reimbursement levels
for the substances. For example, in 2009, over 80% of
olanzapine purchases were reimbursed according to the
higher special refund category compared to about 30% of
quetiapine purchases [16]. If a patient decides to purchase
a product which belongs to a reference price group and is
priced above the reference price, his share of the cost in
the higher special refund category can be considerably
higher than the fixed co-payment of €3.00 per purchase.Table 3 Impact of generic substitution and reference pricing
Level before generic substitution and reference pricing (β0)
Trend before generic substitution and reference pricing (β1)
Level change after generic substitution and reference pricing (β2)
Trend change after generic substitution and reference pricing (β3)This might influence patients’ willingness to switch to a
reference-priced product, and therefore influence the
manufacturers’ willingness to price their products at max-
imum to the reference price. As the higher special refund
category can be interpreted as a proxy for illness severity,
it is also possible that the patients purchasing olanzapine
have a more serious condition and have therefore more
restricted financial resources. This might also influence
the manufacturers’ willingness to price their products at
maximum to reference price.on the daily cost of olanzapine in Finland
Estimate 95% CI P
4.9495 4.8113, 5.0877 <0.0001
−0.0068 −0.0127, −0.0009 0.0257
−1.5789 −1.6986, −1.4592 <0.0001
−0.1229 −0.1470, −0.0988 <0.0001
Table 4 Impact of generic substitution and reference pricing on the daily cost of quetiapine in Finland
Estimate 95% CI P
Level before generic substitution and reference pricing (β0) 6.0130 5.8591, 6.1669 <0.0001
Trend before generic substitution and reference pricing (β1) −0.0248 −0.0311, −0.0185 <0.0001
Level change after generic substitution and reference pricing (β2) −1.0493 −1.1634, −0.9352 <0.0001
Trend change after generic substitution and reference pricing (β3) −0.0506 −0.0757, −0.0254 0.0002
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tation of reference pricing had the largest and the
smallest impact on costs, olanzapine and clozapine, the
differences can partly be explained by the simultaneous
entering to reference pricing and generic substitution in
the case of olanzapine. The sales volumes can also partly
explain the differences. As the consumption of olanza-
pine was higher than that of clozapine, the incentive
for the manufactures of olanzapine to take part in price
competition was most probably greater, even though there
were only a few manufacturers operating in the market.
The low number of generic olanzapine manufacturers can,
in turn, be explained by international markets, as in many
countries olanzapine was still under patent protection
during our study period.
In the case of risperidone, manufacturers anticipated
the forthcoming generic substitution and lowered their
prices one month before the system was implemented.
One reason for this action could be that the manufac-
turers already operating in the market were trying to
control the incentive for new competitors to enter the
market. Also, as risperidone had lost its international
patent exclusivity already in 2007, it is possible that
manufacturers based their pricing decisions in Finland
on international price levels. Nevertheless, in our study
the additional impact of reference pricing to prior imple-
mented generic substitution remained surprisingly low
indicating that generic substitution is effective in pro-
moting price competition. Our results are in contrast to
earlier studies which have indicated that reference pri-
cing produces more significant price decreases in the
sub-markets where drugs were already facing generic
competition prior to reference pricing [7].
For all of the antipsychotics studied, the number of
patients purchasing the products increased during our
study period. The increase was especially high forTable 5 Impact of generic substitution and reference pricing
Estimate
Level before generic substitution (β0) 6.2567
Trend before generic substitution (β1) 0.0226
Pre-effect to generic substitution (β2) −1.4291
Level change after generic substitution (β3) −1.3164
Trend change after generic substitution (β4) −0.0407
Level change after reference pricing (β5) −0.7895quetiapine, for which the number of purchasing indi-
viduals more than doubled between 2006 and 2010.
This can partially be due to decrease in prices, but also
the use of quetiapine for a spectrum of new indications,
for example for sleep disorders, can explain the
phenomenon. However, as the underlying purpose of ref-
erence pricing is to contain pharmaceutical expenditures,
potential increases in demand of pharmaceutical products
due to lower prices should be studied. Besides this, there
are other important issues related to reference pricing
which are beyond the scope of this study. For instance, ref-
erence pricing has been criticized for potentially adverse
effects on the health of those who switch from one
product to another, as well as negatively affecting the
intensity of pharmaceutical research and introduction of
new medicines [25]. However, systematic reviews exam-
ining the effects of reference pricing have found no asso-
ciation between reference pricing and health outcomes,
though more evidence is still needed [7,26]. This might be
especially important with therapeutic groups such as anti-
psychotics where patients are often regarded as particu-
larly vulnerable and where medication adherence has been
shown to be strongly related to hospitalisations [27,28].
The decision to include pharmaceuticals protected by
analogy process patents to the scope of generic substitu-
tion in Finland caused heated debate. For example, the
Office of the United States Trade Representative added
Finland to its Special 301 report watch list because of
concerns about the lack of product patent protection for
certain top-selling U.S. pharmaceutical products [29]. It
was also claimed that the decision will cause irreversible
damage to Finland’s reputation and innovation infra-
structure. This would in long term affect negatively the
nation’s pharmaceutical expenditures and launching of
new and innovative drugs. For example, a study analyzing
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Figure 2 Observed and predicted daily cost of risperidone and the forecast cost had generic substitution and reference pricing not
been implemented (EUR).
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pected prices or small potential sales volumes have fewer
launches and longer launch delays [30]. However, so far
there is no research evidence that the adopted reference
price system would have affected patients’ access to new
innovative drugs while cost savings to the society and
patients have been demonstrated [31].
Our study is based on a national prescription register.
Such a large database gives a comprehensive basis to
study the impact of interventions on drug prices. A limi-
tation of this study is that DDDs were used as a proxy of
a daily dosage. DDD is a statistical unit of measurement
and does not necessarily reflect the prescribed daily
doses. Nevertheless, DDD is an internationally well ac-
cepted and used unit in drug utilisation studies and
therefore the best available measure for this study. Also,
an international study found that the DDD system is
a reliable tool for standardizing antipsychotic doses in
drug utilization research [32]. A further limitation is that
the time period in our study only covered the first year
after reference pricing was implemented, and, therefore,
the effects can only be seen in the short run. However,
international experiences have suggested that reference
pricing is effective in forcing prices down to the reference
price, but there are no incentives for manufacturers to fur-
ther reduce the prices [33]. Experiences from Germany
also suggest that though the prices of drugs included
in reference pricing decline, branded drug manufacturersTable 6 Absolute and relative effects of the interventions to t
models







bInterventions: generic substitution and reference pricing implemented simultaneou
cInterventions: generic substitution and reference pricing implemented separately.compensate for this by increasing the price of those prod-
ucts that are not subject to the policy [8,34]. This topic is
beyond the scope of this study but warrants future
research. In Finland the drug prices are strictly regulated,
and increasing the prices of products already on the
market is difficult. Increases in prices can, however, be
achieved e.g. by launching new products, which in many
cases add little innovation but are highly priced [34]. On
the other hand, it has been suggested that though refer-
ence pricing encourages generic entry and reduces prices,
the decline in off-patent drug costs might be even faster
in settings where there is no price regulation such as refer-
ence pricing [35]. One explanation for this is a so-called
ratchet effect: unless justified by increased input costs, low
prices will in general be difficult to increase again, and
therefore products are priced higher than they would be
in an unregulated environment [36]. Intense price compe-
tition can also have unintended consequences. It can lead
to a downward price spiral which prevents profit making
and results in manufacturers withdrawing from the mar-
ket. In our study, there is no evidence of manufacturers
withdrawing from the market because of price spiral ei-
ther during generic substitution or after reference pricing
was implemented. However, the time period of our study
only covered the first year of reference price system, and
possible long term effects warrant further research
[37]. Further research is also needed on whether the
decision of the originator brand to take part in pricehe average daily cost, estimated from the regression
ervention/-s Absolute change Relative change
Euros 95% CI % 95% CI
−0.6416 −0.8355, −0.4461 −29.9 −37.6, −21.8
−3.0537 −3.3425, −2.7660 −66.3 −70.7, −61.8
−1.6565 −1.9443, −1.3670 −34.9 −39.8, −29.7
−3.2048 −3.4034, −3.0069 −43.3 −44.9, −41.5
sly.
Koskinen et al. Health Economics Review 2014, 4:9 Page 9 of 10
http://www.healtheconomicsreview.com/content/4/1/9competition or not has an effect on the intensity of the
competition. In our data some originator brands took
part in the price competition while some did not.
An interrupted time series design is a strong quasi-
experimental approach while segmented regression ana-
lysis is a powerful statistical method when evaluating
longitudinal effects of interventions. One of the greatest
strengths of this approach is its comprehensible and
graphically intuitive presentation of results. The method
is especially well suited for interventions that take place
abruptly and it has been widely used in health policy
evaluations [20,38]. However, there are some potential
methodological challenges associated with the method.
One of the major potential biases for interrupted time
series designs are simultaneously occurring interventions.
Also seasonal variations in time series are possible. As a
rule of thumb, at least 12 time points are needed before
and after the intervention in order to detect seasonal
variation within the data. As we had 39 data points before
reference pricing and 12 data points after reference pri-
cing, we were able to control the seasonal variation. Thus,
as no other changes occurred in the reimbursement
system or in the health care system during the study
period, we can be confident that the observed changes in
the daily cost of the four antipsychotic classes were due to
the implementation of generic substitution and reference
pricing.
In 2009 and 2010, the price competition induced by
reference pricing and extended generic substitution gen-
erated substantial savings in Finland both in the sales of
medicines and the reimbursement expenditures, and the
total savings were greatest in the antipsychotics group
[31,39].
Conclusions
Reference pricing produced substantial reduction of the
daily cost of antipsychotic medication in Finland during
the first year of application, but the intensity of the impact
varied between the active substances. Our results suggest
that the additional cost savings from reference pricing
that followed the adoption of generic substitution, are
comparatively low.
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